Summary of findings 6. SSRIs compared to MAOIs for adults with panic disorder.
| SSRIs compared to MAOIs for adults with panic disorder | ||||||
| Patient or population: adults with panic disorder Settings: outpatient Intervention: SSRI Comparison: MAOI | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| MAOI | SSRI | |||||
| failure to respond Follow‐up: 8‐12 weeks | 264 per 1000 | 296 per 1000 (219 to 401) | RR 1.12 (0.83 to 1.52) | 396 (2 studies) | ⊕⊕⊕⊝ moderate1 | |
| total number of dropouts Follow‐up: 12 weeks | 67 per 1000 | 67 per 1000 (5 to 970) | RR 1.00 (0.07 to 14.55) | 30 (1 study) | ⊕⊕⊝⊝ low2 | |
| failure to remit Follow‐up: 8 weeks | 467 per 1000 | 434 per 1000 (346 to 546) | RR 0.93 (0.74 to 1.17) | 366 (1 study) | ⊕⊕⊕⊝ moderate3 | |
| panic symptoms | See comment | See comment | Not estimable | 0 (0) | See comment | No studies provided data for this outcome |
| number of dropouts due to adverse events Follow‐up: 8 weeks | 60 per 1000 | 76 per 1000 (36 to 163) | RR 1.26 (0.59 to 2.70) | 366 (1 study) | ⊕⊕⊝⊝ low4 | |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Downgraded one point due to imprecision: 95% CI ranges from no difference to appreciable benefit with MAOIs 2 Downgraded two points due to imprecision: number of individuals included in the trial is very low (= 30) and 95% CI is very wide, ranging from appreciable benefit with SSRIs to appreciable benefit with MAOIs; only one study provides data 3 Downgraded one point due to imprecision: even though the number of individuals included in the analysis is not low, only one study provides data 4 Downgrded two points due to imprecision: 95% CI ranges from appreciable benefit with SSRIs to appreciable benefit with MAOIs; only one study provides data.